Aardvark Therapeutics Stock Price, News & Analysis

Aardvark Therapeutics (NASDAQ:AARD), a clinical-stage biopharmaceutical company, will present at three major healthcare investor conferences in September 2025. The company, which focuses on developing novel small-molecule therapeutics for metabolic diseases, will participate in the Cantor Fitzgerald Global Healthcare Conference (September 3), Morgan Stanley Global Healthcare Conference (September 8), and H.C. Wainwright Global Investment Conference (September 10).

All presentations will be available via live webcast on the company's website, with recordings accessible for approximately one month afterward.

Aardvark Therapeutics (NASDAQ:AARD) reported Q2 2025 financial results and provided significant pipeline updates. The company ended Q2 with $141.8 million in cash, supporting operations into 2027. Net loss increased to $14.4 million from $5.4 million year-over-year.

Key developments include plans to expand the Phase 3 HERO trial of ARD-101 for Prader-Willi Syndrome to include patients under 13 years old. New preclinical data for ARD-201 showed promising results in preventing weight rebound after GLP-1RA discontinuation, leading to two new Phase 2 trials: POWER and STRENGTH, replacing the previously planned EMPOWER trial.

The company strengthened its leadership team with strategic appointments across scientific, commercial, regulatory, and legal functions.

Aardvark Therapeutics (NASDAQ:AARD) has announced promising preclinical data for ARD-201, its novel obesity treatment candidate. In diet-induced obesity (DIO) mouse studies, ARD-201 demonstrated 19% body weight reduction after 30 days as a monotherapy. The oral treatment showed significant potential in three key areas: preventing weight regain after GLP-1RA discontinuation, standalone weight loss therapy, and enhanced efficacy when combined with low-dose tirzepatide.

The company plans to advance ARD-201 into two Phase 2 trials: The POWER trial (2H 2025) will evaluate weight maintenance after GLP-1RA discontinuation, while the STRENGTH trial (1H 2026) will assess ARD-201's effectiveness alone and in combination with GLP-1RA therapy. These trials replace the previously planned EMPOWER trial.

Aardvark Therapeutics (NASDAQ: AARD), a clinical-stage biopharmaceutical company developing small-molecule therapeutics for metabolic diseases, has granted inducement stock options to two new employees. The grants, made between July 8-14, 2025, consist of options to purchase 10,372 shares of common stock.

The options were granted under the company's 2025 Inducement Equity Incentive Plan at exercise prices of $13.04 and $12.11, matching the closing prices on the respective grant dates. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly at 1/48th of the total shares.

Aardvark Therapeutics (NASDAQ:AARD) announced its participation in the 2025 United in Hope Conference for Prader-Willi syndrome (PWS) from June 24-28 in Phoenix, Arizona.

The company will present previously disclosed Phase 2 data for ARD-101, highlighting the drug's favorable safety profile and early evidence of reduced hyperphagia in PWS patients. The presentation will also discuss how these findings informed their ongoing Phase 3 HERO study.

Chief Medical Officer Dr. Manasi Jaiman will participate in a panel discussion about the Phase 3 HERO study, and company representatives will be available at their booth to engage with attendees.

Aardvark Therapeutics (NASDAQ: AARD) has announced key leadership appointments to strengthen its executive team. Timothy Kieffer, Ph.D., joins as Chief Scientific Officer, bringing expertise in diabetes research from ViaCyte and Fractyl Health. Danny Villeneuve becomes Chief Commercial Officer, with over 20 years of experience in biopharmaceutical commercialization. Terrie Kellmeyer, Ph.D., is appointed Senior Vice President of Regulatory Affairs, contributing 30 years of regulatory strategy experience. Christian Zapf, J.D., joins as General Counsel with extensive biotechnology legal experience. These appointments come as Aardvark advances its Phase 3 HERO study of ARD-101 for treating hyperphagia in Prader-Willi Syndrome. Additionally, the company granted stock options to two new employees totaling 137,500 shares at $9.89 per share, vesting over four years.

Aardvark Therapeutics (NASDAQ: AARD) reported its Q1 2025 financial results and business updates. The company successfully completed its IPO in February 2025, raising $87.5 million in net proceeds. As of March 31, 2025, Aardvark had $151.3 million in cash and investments, expected to fund operations into 2027.

The company's lead candidate, ARD-101, is in Phase 3 HERO trial for treating hyperphagia in Prader-Willi Syndrome (PWS), with data readout expected in early 2026. For Q1 2025, R&D expenses increased to $7.8 million from $1.2 million in Q1 2024, while G&A expenses rose to $2.7 million from $0.9 million. Net loss widened to $9.3 million compared to $2.2 million in the prior year.

Aardvark Therapeutics (NASDAQ: AARD), a clinical-stage biopharmaceutical company specializing in small-molecule therapeutics for metabolic diseases, has announced its participation in three major healthcare investor conferences in May 2025:

- Bank of America Global Healthcare Conference in Las Vegas on May 15 at 12:35 p.m. ET
- H.C. Wainwright BioConnect Investor Conference in New York on May 20 at 3:30 p.m. ET
- RBC Capital Markets Global Healthcare Conference in New York on May 21 at 2:35 p.m. ET

Live webcasts will be available on the company's website with recordings accessible for approximately one month after each presentation.

Aardvark Therapeutics (NASDAQ: AARD) reported its full year 2024 financial results and business highlights. The company's lead candidate ARD-101 showed promising results in a Phase 2 trial for Prader-Willi Syndrome (PWS), demonstrating up to 16-point HQ-CT reduction in hyperphagia and improvements in body composition over 28 days.

The company successfully completed its IPO in February 2025, raising $97.9 million in gross proceeds. Financial results show cash position of $73.7 million as of December 31, 2024. R&D expenses increased to $17.4 million from $4.5 million in 2023, while G&A expenses rose to $5.3 million from $2.2 million. Net loss widened to $20.6 million from $7.2 million in 2023.

Key upcoming milestones include Phase 2 HONOR trial initiation for hypothalamic obesity and Phase 2 EMPOWER trial for ARD-201 in H2 2025, with Phase 3 HERO trial topline data expected in early 2026.